Bicycle Therapeutics Limited
Meditrina Building
Babraham Research Campus
Cambridge
CB22 3AT
United Kingdom
Tel: 44-0-1223-497-390
Fax: 44-0-7798-791-337
Website: http://www.bicycletherapeutics.com/
182 articles about Bicycle Therapeutics Limited
-
Bicycle Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
4/2/2024
Bicycle Therapeutics plc, a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide technology, announced that management will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on April 9, 2024, at 11 a.m. ET.
-
Bicycle Therapeutics to Present at the AACR Annual Meeting 2024
3/5/2024
Bicycle Therapeutics plc announced the acceptance of three abstracts for poster presentation at the American Association for Cancer Research Annual Meeting 2024, taking place in San Diego on April 5-10.
-
Bicycle Therapeutics to Participate in Upcoming Investor Conferences - February 28, 2024
2/28/2024
Bicycle Therapeutics plc today announced that management will participate in the following investor conferences in March.
-
Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results
2/20/2024
Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided recent corporate updates.
-
Bicycle Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
2/7/2024
Bicycle Therapeutics plc technology, today announced that management will participate in a fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 14, 2024, at 10 a.m. ET.
-
Bicycle Therapeutics Provides Data Updates for Three Clinical Programs and Strategy Overview at First R&D Day
12/14/2023
Bicycle Therapeutics is hosting a Research & Development Day for investors and analysts in New York to provide clinical updates for BT8009, BT7480 and BT5528, and an overview of the company’s strategy and pipeline opportunities.
-
Bicycle Therapeutics to Host R&D Day on December 14
11/30/2023
Bicycle Therapeutics plc today announced that the company will host its first Research and Development (R&D) Day on Thursday, December 14.
-
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results and Announces Upcoming R&D Day
11/2/2023
Bicycle Therapeutics plc reported financial results for the third quarter ended September 30, 2023, and provided recent corporate updates.
-
Bicycle Therapeutics to Participate in Upcoming Investor Conferences - October 30, 2023
10/30/2023
Bicycle Therapeutics plc today announced that management will participate in the following investor conferences in November.
-
Bicycle Therapeutics Selected to Participate in FDA Program to Expedite Commercial Manufacturing Readiness of BT8009 for Metastatic Bladder Cancer
10/19/2023
Program intended to facilitate CMC development for selected therapies with expedited clinical development timeframes to help patients get access sooner.
-
Bicycle Therapeutics Announces Expedited Development Plan for BT8009 in Metastatic Bladder Cancer
9/11/2023
Bicycle Therapeutics today announced the company will proceed with its plan to expedite development of BT8009 for metastatic bladder (urothelial) cancer following recent discussions with the U.S. Food and Drug Administration (FDA).
-
Bicycle Therapeutics to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
9/5/2023
Bicycle Therapeutics (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference in New York on September 12, 2023, at 10:10 a.m. ET.
-
Bicycle Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
8/3/2023
Bicycle Therapeutics Limited plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the second quarter ended June 30, 2023 and provided recent corporate updates.
-
Bicycle Therapeutics Announces Closing of Public Offering of American Depositary Shares and Non-Voting Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
7/18/2023
Bicycle Therapeutics plc today announced the closing on Monday, July 17, 2023 of its underwritten public offering of 6,117,648 American Depositary Shares (“ADSs”), each representing one ordinary share.
-
Bicycle Therapeutics Announces Pricing of $200 Million Public Offering of American Depositary Shares and Non-Voting Ordinary Shares
7/13/2023
Bicycle Therapeutics plc announced the pricing of an underwritten public offering of 9,411,766 American Depositary Shares, each representing one ordinary share and, in lieu of ADSs to investors that so choose, non-voting ordinary shares, each at a price to the public of $21.25 per share, for gross proceeds of approximately $200.0 million.
-
Bicycle Therapeutics Announces Proposed $200 Million Public Offering of American Depositary Shares and Non-Voting Ordinary Shares
7/12/2023
Bicycle Therapeutics plc announced that it has commenced an underwritten public offering of $200 million of American Depositary Shares, each representing one ordinary share and, in lieu of ADSs to investors that so choose, non-voting ordinary shares.
-
Bicycle Therapeutics Appoints Alethia Young as Chief Financial Officer
6/23/2023
Bicycle Therapeutics plc today announced the appointment of Alethia Young as its new Chief Financial Officer, effective July 17th.
-
Bicycle Therapeutics to Participate in the TD Cowen Radiopharmaceutical Innovation Summit
6/13/2023
Bicycle Therapeutics plc, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide technology, announced that management will participate in a fireside chat at the TD Cowen Radiopharmaceutical Innovation Summit on June 20th, 2023 at 12:30 p.m. ET.
-
Bicycle Therapeutics to Participate in the Jefferies Healthcare Conference - May 31, 2023
5/31/2023
Bicycle Therapeutics plc today announced that management will participate in a fireside chat at the Jefferies Healthcare Conference in New York, NY on June 7th, 2023 at 10:30 a.m. ET.
-
Bicycle Therapeutics and Orano Med Present Preclinical Bicycle® Radio-Conjugate Data at TIDES 2023
5/11/2023
Bicycle Therapeutics plc (NASDAQ: BCYC) and Orano Med, two biotechnology companies respectively, announce pre-clinical results.